On February 14, 2024 Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, reported that members of its senior management team will participate in two upcoming investor conferences (Press release, Ashvattha Therapeutics, FEB 14, 2024, View Source [SID1234640082]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Details:
BIO CEO & Investor Conference
Format: Corporate Presentation
Date: Tuesday, February 27, 2024
Time: 11:45 – Noon ET
Location: The New York Marriott Marquis
Ashvattha’s Co-Founder and Chief Executive Officer, Jeffrey Cleland, Ph.D., and Chief Financial Officer, Paul Cayer, will be available for one-on-one meetings. If you are interested in a meeting, please reach out via the BIO One-on-One Partnering system.
Evercore ISI 2024 Emerging Biotech Conference
Format: Fireside Chat
Date: Thursday, February 29, 2024
Time: 11:20 – 11:50 am ET
Location: Virtual
Members of Ashvattha’s management team will provide an update on the company’s multiple Phase 2 clinical trials and upcoming data readouts.